Perfume compositions – Perfume compositions – With preservative – stabilizer – or fixative
Reexamination Certificate
2006-10-31
2006-10-31
Andres, Janet L. (Department: 1649)
Perfume compositions
Perfume compositions
With preservative, stabilizer, or fixative
C530S300000, C530S350000, C530S351000, C530S402000, C435S007210, C435S069100, C424S085100, C436S501000
Reexamination Certificate
active
07129203
ABSTRACT:
Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of deleting at least one amino acid residue on the protein, replacing the at least one amino acid residue with an amino acid residue that does not react with polyethylene glycol, and contacting the protein with polyethylene glycol under conditions sufficient to conjugate the polyethylene glycol to the protein. This advantageous retention of a desired protein activity is attributed to the availability of one or more protein binding sites which is unaltered in the conjugation process and thus remains free to interact with a binding partner ligand or cognate subsequent to the conjugation process.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5235028 (1993-08-01), Barany et al.
patent: 5514572 (1996-05-01), Veronese et al.
patent: 5776895 (1998-07-01), Alber et al.
patent: 6433158 (2002-08-01), Pettit
patent: 6441136 (2002-08-01), Pettit
patent: WO 98/05824 (1989-06-01), None
patent: WO 94/13322 (1994-06-01), None
patent: WO 94/20069 (1994-09-01), None
patent: WO 96/11213 (1996-04-01), None
patent: WO 9711178 (1997-03-01), None
patent: WO 98/35026 (1998-08-01), None
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation,”Cell,73:431-445, May 7, 1993.
Benhar, et al., “Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization”,Bioconjugate Chem.5:321-326, 1994.
Delgado et al., “The Uses and Properties of PEG-Linked Proteins”,Critical Reviews in Therapeutic Drug Carrier Systems9:249-304, 1992.
Felix, Arthur M., “Site-Specific Poly(ethylene glycol)ylation of Peptides,”ACS Symposium Series 680:ch 16, 218-239, 1997.
Gombotz et al., “Biodegradable Polymers for Protein and Peptide Drug Delivery”,Bioconjugate Chemisty6:332-351, 1995.
Goodson et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site”,Bio/Technology8:343-46, Apr. 1990.
Hershfield, M. S. et al., “Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol,”Proc. Natl. Acad. Sci. USA,88:7185-7189, Aug. 1991.
Kinstler et al., “Characterization and Stability of N-terminally PEGylated rhG-CSF”,Pharmaceutical Research13:996-1002, 1996.
Lu, Yi-An and Felix, Arthur M., Pegylated peptides II,Int. J. Peptide Protein Res.43:127-138, 1994.
Mohler et al., “Soluble Tumor Necrosis Factor (TNF) Receptors are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists”,The Journal of Immunology151:548-1561, 1993.
Onozaki et al., “Human Interleukin 1 is a Cytocidal Factor for Several Tumor Cell Lines”,The Journal of Immunology135:3962-68, Dec. 1985.
Pettit et al., “Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling”,The Journal of Biological Chemistry272:2312-2318, 1997.
Pettit et al., “Site Protected PEGyolation of Recombinant (p75) Tumor Necrosis Factor Receptor,”Division of Polymer Chemistry, Inc. American Chemical Society38:1, 574-575, Apr. 1997.
Sartore et al., “Accurate Evaluation Method of the Polymer Content in Monomethoxy (Polyethylene Glycol) Modified Proteins Based on Amino Acid Analysis”,Applied Biochemistry and Biotechnology31:213-222, 1991.
Urrutigoity et al., “Biocatalysis in Organic Solvents with a Polymer-Bound Horseradish Peroxidase”,Biocatalysis2:145-149, 1989.
Wang, et al., “Polyethylene glycol-modified chimeric toxin composed of transforming growth factor α and pseudomonas exotoxin”,Cancer Research53:4588-4594, 1993.
Zalipsky, S., “Chemistry of polyethylene glycol conjugates with biologically active molecules,”Advanced Drug Delivery Reviews,16:157-182, 1995.
Andres Janet L.
Brannock Michael
Henry Janis C.
Immunex Corporation
Wrona Thomas J.
LandOfFree
Site specific protein modification does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Site specific protein modification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Site specific protein modification will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3661853